person · Reporting owner

Zakrzewski Joseph S

Disclosed activity across 6 companies

Tapewire entity: 23401
SEC CIK: 0001331852

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMARIN CORP PLC\UKAMRN · Entity 5970	Director	December 14, 2021	December 17, 2021
AN2 Therapeutics, Inc.ANTX · Entity 1085	Director	August 14, 2026	August 14, 2026
Cyteir Therapeutics, Inc.CYT · Entity 92707	Director	February 06, 2024	February 08, 2024
INSULET CORPPODD · Entity 3516	Director	May 17, 2017	May 18, 2017
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	February 25, 2022	March 01, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMARIN CORP PLC\UK

Report date December 14, 2021 · Filed December 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	194,547	Reported balance After 2021-12-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2021-12-14 · Purchase · Acquired 10,000 · Balance 194,547 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Ordinary SharesSEC Table I · non-derivative	Direct	196,547	Reported balance After 2021-12-15 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2021-12-15 · Purchase · Acquired 2,000 · Balance 196,547 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Please see the section titled "Remarks" below for additional information.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Please see the section titled "Remarks" below for additional information.

AN2 Therapeutics, Inc.

Report date August 14, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2026-08-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-08-14 · Gift · Disposed 405,880 · Balance 0 F1: Reflects a gift of shares to the children of the Reporting Person. F2: The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.
Common StockSEC Table I · non-derivative	Direct	145,538	Reported balance Holding disclosure · report date 2026-08-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 145,538

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a gift of shares to the children of the Reporting Person.

F2: The shares are held by Nancy Zakrzewski TTEE Z3 Trust U/A DTD 11/25/14 ("Z3 Trust"). The Reporting Person disavows beneficial ownership of the shares held by Z3 Trust.

Cyteir Therapeutics, Inc.

Report date February 06, 2024 · Filed February 08, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	227,439	Reported balance After 2024-02-06 transaction · row 1 1 source row Row 1 · 2024-02-06 · Exercise / conversion · Acquired 14,150 · Balance 227,439
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.69 · Expires 2033-02-03	Direct	0	Reported balance After 2024-02-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-06 · Exercise / conversion · Disposed 14,150 · Balance 0
Common StockSEC Table I · non-derivative	IndirectSee Footnote	149,051	Reported balance Holding disclosure · report date 2024-02-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 149,051 F1: Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.

INSULET CORP

Report date May 17, 2017 · Filed May 18, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,558	Reported balance After 2017-05-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-05-17 · Grant · Acquired 2,709 · Balance 30,558 F1: The 2,709 restricted stock units vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.60 · Expires 2027-05-17	Direct	3,587	Reported balance After 2017-05-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-05-17 · Grant · Acquired 3,587 · Balance 3,587

Filing footnotes · ownership attribution and instrument terms

F1: The 2,709 restricted stock units vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.

F2: Includes 1,010 restricted stock units granted on May 13, 2015, which vest on April 30, 2018, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date.

SANGAMO THERAPEUTICS, INC

Report date February 25, 2022 · Filed March 01, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	60,700	Reported balance After 2022-02-25 transaction · row 1 1 source row Row 1 · 2022-02-25 · Grant · Acquired 12,500 · Balance 60,700 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.90 · Expires 2032-02-24	Direct	25,000	Reported balance After 2022-02-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-25 · Grant · Acquired 25,000 · Balance 25,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the first anniversary of the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date November 19, 2021 · Filed November 22, 2021

Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Other · Disposed 34,499 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $27.97	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $30.17	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.20	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99	Direct	Reported balance After 2021-11-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-11-19 · Disposition to issuer · Disposed 8,185 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53	Direct	Reported balance After 2021-11-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 14, 2021 Filed Jun 17, 2021 00:07 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	45,953	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001562180-21-004331 · primarydocument.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,953 Underlying: Ordinary Shares · 45,953 shares Expires 2031-06-14 F1 · derivative.exercise_date: On June 14, 2021, the Reporting Person was granted an option to purchase 45,953 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of June 14, 2021 or (ii) the Issuer's annual general meeting of shareholders in 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	10,000	$0.00 Strike: $24.11	$0.00	Disclosure SEC source: 0001179110-21-004227 · edgar.xml · derivative · entry 5 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,100	$142.27	$156,497.00	Disclosure SEC source: 0001179110-21-004227 · edgar.xml · nonDerivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,499 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.07 to $142.57 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,152	$141.28	$304,034.56	Disclosure SEC source: 0001179110-21-004227 · edgar.xml · nonDerivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,599 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.01 to $142.00 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	6,748	$140.31	$946,811.88	Disclosure SEC source: 0001179110-21-004227 · edgar.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,751 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.01 to $140.99 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
April 05, 2021 Filed Apr 5, 2021 20:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	10,000	$24.11	$241,100.00	Disclosure SEC source: 0001179110-21-004227 · edgar.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
April 01, 2021 Filed Apr 2, 2021 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	10,000	$0.00 Strike: $24.11	$0.00	Disclosure SEC source: 0001179110-21-004122 · edgar.xml · derivative · entry 6 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant. Read SEC document
April 01, 2021 Filed Apr 2, 2021 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,600	$135.67	$217,072.00	Disclosure SEC source: 0001179110-21-004122 · edgar.xml · nonDerivative · entry 5 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,499 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.64 to $135.73 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document
April 01, 2021 Filed Apr 2, 2021 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	1,700	$135.22	$229,874.00	Disclosure SEC source: 0001179110-21-004122 · edgar.xml · nonDerivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,099 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.62 to $135.51 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document
April 01, 2021 Filed Apr 2, 2021 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	6,596	$134.27	$885,644.92	Disclosure SEC source: 0001179110-21-004122 · edgar.xml · nonDerivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,799 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.62 to $134.61 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document
April 01, 2021 Filed Apr 2, 2021 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	104	$132.61	$13,791.44	Disclosure SEC source: 0001179110-21-004122 · edgar.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,395 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.57 to $133.50 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document
April 01, 2021 Filed Apr 2, 2021 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	10,000	$24.11	$241,100.00	Disclosure SEC source: 0001179110-21-004122 · edgar.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:07 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	16,400	$0.00 Strike: $11.19	$0.00	Disclosure SEC source: 0001209191-21-015514 · doc4.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2031-02-24 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:07 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	8,200	$0.00	$0.00	Disclosure SEC source: 0001209191-21-015514 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,200 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document
January 29, 2021 Filed Feb 2, 2021 19:00 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	3,222	$0.00 Strike: $115.53	$0.00	Disclosure SEC source: 0001179110-21-001114 · edgar.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222 Underlying: Common Stock · 3,222 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document
January 29, 2021 Filed Feb 2, 2021 19:00 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	1,622	$0.00	$0.00	Disclosure SEC source: 0001179110-21-001114 · edgar.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,499 Read SEC document
October 21, 2020 Filed Oct 23, 2020 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001562180-20-006417 · primarydocument.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 100,000 shares Expires 2020-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
October 21, 2020 Filed Oct 23, 2020 00:03 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	100,000	$3.40	$340,000.00	Disclosure SEC source: 0001562180-20-006417 · primarydocument.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · balance_after: Please see the section titled "Remarks" below for additional information. Read SEC document
July 13, 2020 Filed Jul 16, 2020 00:09 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	27,191	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-005127 · primarydocument.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,191 Underlying: Ordinary Shares · 27,191 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On July 13, 2020, the Reporting Person was granted 27,191 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 13, 2020 Filed Jul 16, 2020 00:09 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	34,805	$0.00 Strike: $6.62	$0.00	Disclosure SEC source: 0001562180-20-005127 · primarydocument.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,805 Underlying: Ordinary Shares · 34,805 shares Expires 2030-07-13 F1 · derivative.exercise_date: On July 13, 2020, the Reporting Person was granted an option to purchase 34,805 Ordinary Shares under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of July 13, 2020 or (ii) the Issuer's annual general meeting of shareholders in 2021. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 18, 2020 Filed May 20, 2020 21:22 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $10.46	$0.00	Disclosure SEC source: 0001209191-20-030966 · doc4.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document
May 18, 2020 Filed May 20, 2020 21:22 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-20-030966 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
May 18, 2020 Filed Jun 3, 2020 20:30 UTC Amendment	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $10.46	$0.00	Disclosure SEC source: 0001209191-20-034033 · doc4a.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document
May 18, 2020 Filed Jun 3, 2020 20:30 UTC Amendment	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	10,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034033 · doc4a.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. Read SEC document
March 17, 2020 Filed Mar 19, 2020 21:00 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	PurchaseCommon Stock	5,000	$4.99	$24,950.00	Disclosure SEC source: 0001209191-20-020303 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. Read SEC document
March 13, 2020 Filed Mar 13, 2020 21:41 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	PurchaseCommon Stock	5,000	$5.67	$28,350.00	Disclosure SEC source: 0001209191-20-019005 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. Read SEC document
March 12, 2020 Filed Mar 13, 2020 21:41 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	PurchaseCommon Stock	15,000	$6.31	$94,650.00	Disclosure SEC source: 0001209191-20-019005 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · balance_after: Includes 2,500 shares of common stock subject to restricted stock units ("RSUs") granted on June 10, 2019. The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to Issuer's 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. Read SEC document
January 22, 2020 Filed Jan 24, 2020 17:59 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantOption to Purchase Common Stock · Derivative	8,185	$0.00 Strike: $52.99	$0.00	Disclosure SEC source: 0001179110-20-000782 · edgar.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,185 Underlying: Common Stock · 8,185 shares Expires 2030-01-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document
January 22, 2020 Filed Jan 24, 2020 17:59 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	GrantCommon Stock	1,377	$0.00	$0.00	Disclosure SEC source: 0001179110-20-000782 · edgar.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,877 Read SEC document
January 07, 2020 Filed Jan 9, 2020 16:36 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionOption to Purchase Common Stock · Derivative	18,750	$0.00 Strike: $3.88	$0.00	Disclosure SEC source: 0001179110-20-000436 · edgar.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant. Read SEC document
January 07, 2020 Filed Jan 9, 2020 16:36 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	Exercise / conversionCommon Stock	18,750	$3.88	$72,750.00	Disclosure SEC source: 0001179110-20-000436 · edgar.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2020 Filed Jan 4, 2020 02:30 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	300,000	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001209191-20-001469 · doc4.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 300,000 shares Expires 2020-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
January 03, 2020 Filed Jan 4, 2020 02:30 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	300,000	$20.94	$6,282,870.00	Disclosure SEC source: 0001209191-20-001469 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,547 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.71 to $21.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
January 03, 2020 Filed Jan 4, 2020 02:30 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	300,000	$3.40	$1,020,000.00	Disclosure SEC source: 0001209191-20-001469 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 16, 2019 Filed Dec 19, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001209191-19-061213 · doc4.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,542 Underlying: Ordinary Shares · 100,000 shares Expires 2021-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
December 16, 2019 Filed Dec 19, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	100,000	$25.83	$2,583,380.00	Disclosure SEC source: 0001209191-19-061213 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,547 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.80 to $25.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
December 16, 2019 Filed Dec 19, 2019 01:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	100,000	$9.00	$900,000.00	Disclosure SEC source: 0001209191-19-061213 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 05, 2019 Filed Jul 6, 2019 01:00 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $9.00	$0.00	Disclosure SEC source: 0001209191-19-041364 · doc4.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,542 Underlying: Ordinary Shares · 100,000 shares Expires 2021-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
July 05, 2019 Filed Jul 6, 2019 01:00 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	100,000	$23.82	$2,381,580.00	Disclosure SEC source: 0001209191-19-041364 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,547 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.80 to $23.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
July 05, 2019 Filed Jul 6, 2019 01:00 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	100,000	$9.00	$900,000.00	Disclosure SEC source: 0001209191-19-041364 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
June 18, 2019 Filed Jun 21, 2019 00:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001209191-19-038330 · doc4.xml · derivative · entry 3 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Ordinary Shares · 100,000 shares Expires 2020-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 18, 2019 Filed Jun 21, 2019 00:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	SaleOrdinary Shares	100,000	$19.02	$1,902,090.00	Disclosure SEC source: 0001209191-19-038330 · doc4.xml · nonDerivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,547 F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.98 to $19.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
June 18, 2019 Filed Jun 21, 2019 00:05 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionOrdinary Shares	100,000	$3.40	$340,000.00	Disclosure SEC source: 0001209191-19-038330 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · balance_after: Please see the section title "Remarks" below for additional information. Read SEC document
June 14, 2019 Filed Jun 17, 2019 18:08 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	PurchaseCommon Stock	5,000	$38.05	$190,250.00	Disclosure SEC source: 0001179110-19-007787 · edgar.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.03 to $38.05 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document
June 10, 2019 Filed Jun 12, 2019 21:13 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $9.38	$0.00	Disclosure SEC source: 0001209191-19-036449 · doc4.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document
June 10, 2019 Filed Jun 12, 2019 21:13 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	2,500	$0.00	$0.00	Disclosure SEC source: 0001209191-19-036449 · doc4.xml · nonDerivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
May 20, 2019 Filed May 22, 2019 00:12 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantRestricted Stock Units · Derivative	7,428	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-031866 · doc4.xml · derivative · entry 2 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,428 Underlying: Ordinary Shares · 7,428 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion, with settlement to be made on a deferred basis, specifically upon the non-employee director's separation of service with the Issuer. F4 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted 7,428 RSUs under the Plan. The RSUs vest in equal annual installments over a three-year period, with each installment vesting upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in such year. F5 · derivative.expiration_date: Not applicable. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
May 20, 2019 Filed May 22, 2019 00:12 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	GrantStock Option (Right to Buy) · Derivative	9,658	$0.00 Strike: $16.83	$0.00	Disclosure SEC source: 0001209191-19-031866 · doc4.xml · derivative · entry 1 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,658 Underlying: Ordinary Shares · 9,658 shares Expires 2029-05-20 F1 · derivative.exercise_date: On May 20, 2019, the Reporting Person was granted an option to purchase 9,658 Ordinary Shares under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). The option shall vest and become exercisable in a single annual installment upon the earlier of (i) the anniversary of the grant date of May 20, 2019 or (ii) the Issuer's annual general meeting of shareholders in 2020. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:34 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	36,875	$0.00 Strike: $8.10	$0.00	Disclosure SEC source: 0001209191-19-012808 · doc4.xml · derivative · entry 5 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,875 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
February 22, 2019 Filed Feb 23, 2019 02:34 UTC	AMARIN CORP PLC\UK AMRN · Entity 5970	Exercise / conversionStock Option (Right to Buy) · Derivative	143,750	$0.00 Strike: $8.86	$0.00	Disclosure SEC source: 0001209191-19-012808 · doc4.xml · derivative · entry 4 Zakrzewski Joseph S · CIK 0001331852 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 143,750 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option granted to the Reporting Person is fully vested as of the date hereof. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.